The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Plenty being written in the daily and weekend press about Covid-19 and possible treatments - it would be nice if one or more gave Sareum a mention as potentially offering at least part of a treatment - if only to validate the positive postings from some of the contributors here.
Tim and John probably feel that the options granted to them over the years are enough to compensate them sufficiently if their hard work comes to fruition. Tim and John have nearly 88 mill options each at various prices which if the share price was to reach 2p would give them £1 mill each (with tax implications for the unapproved options). However, with the share price being .32p only 2 of the options are worth anything with a paper gain to them of only £8k each at the moment if they were to cash in (if my maths is right).
The two things I picked out were the TYK2 report due ‘in the near future” from the grant by DoD and also “The Directors will continue to review the potential higher value of a later-stage licensing deal versus the requirement for any extra funding.”
I of course meant 2019 not 2018 in my last post but also was just meaning to say that I didn’t think there would be anything held back for the poster the next day and therefore allowing questions on the results and anything else.
My view is that though the results are for the period ending 30th June 2018, the narrative of the updated results on TYK2 will be given on Tuesday as a post year end addition therefore allowing Q and A’s on them. On Wednesday these updates will be released in poster form, diagrams, flow charts etc. That is all I meant. I may be wrong of course and probably will be.
Presumably when the results are announced on the 15th they will include updates on all fronts as per usual - everything then being in the public domain and nothing would then be a surprise on the 16th and questions on the 15th would be allowed on any subject.
Read the RNS dated 10th Sept - explains all
Today’s RNS was a Trading Statement ahead of the results - last year it was released on 11th Sept and in 2017 on the 22nd August - don’t think this was in response to Thoth at all but just a release they do each year. (This isn’t to rubbish Thoths efforts in trying to get more shareholder updates)
One or two drugs have been named today as likely to be fast tracked - they fall in to the tumour agnostic category ie not specific to any particular type of cancer. Would either SRA737 or SDC1802 fall in to this category? It would be nice to hear something from Sareum on this.
Disappointed with the first part of the webcast where NG stresses that Momelotenib is their lead compound. The next to the last question mentions us though and NG responds by saying they can’t understand the share price following Johann De Bono’s presentation and that they will explore all possibilities to bring it to market as they are morally obliged to do.